Trevena Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena, Inc.

Country	United States
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	23
CEO	Carrie Bourdow

Contact Details

Address: 955 Chesterbrook Boulevard Chesterbrook, Delaware 19087 United States
Phone	610 354 8840
Website	trevena.com

Stock Details

Ticker Symbol	TRVN
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US89532E1091
SIC Code	2836

Key Executives

Name	Position
Carrie L. Bourdow	President, Chief Executive Officer and Chairman
Barry Shin J.D.	Chief Operating Officer
Dr. Mark A. Demitrack M.D.	Senior Vice President and Chief Medical Officer
Dr. Howard A. Rockman M.D.	Scientific Founder, Consultant and Member of Scientific Advisory Board
Katrine Sutton	Principal Financial Officer and principal accounting officer
Robert T. Yoder	Senior Vice President, Chief Business Officer, Head of Commercial Operations and Chief Compliance Officer
Michael Catalano	Vice President of Marketing